Weisheng Pharmaceutical (Shanghai) Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Shanghai China

Primary Industry

Biotechnology

About

Founded in 2018 and based in Shanghai, China, Weisheng Pharmaceutical (Shanghai) Co., Ltd. is an innovative biopharmaceutical company focused on endocrine-related therapeutic areas. The company has set up a R&D and manufacturing base in Suzhou and has branches in Shanghai, Beijing and other cities. The Company's lead drug, lonapegsomatropin, was IND-approved for a Phase 3 clinical trial in China starting in October 2019, and reached the trial's primary endpoint in May 2022. In January 2021, the company closed a round of series B funding. The Company mainly researches and develops endocrine drug products, and its product pipeline includes Lompex Growth Promoter, Paropex Teriparatide, and TransCon CNP, which are mainly used for the treatment of endocrine disorders such as growth hormone deficiency and chondrodysplasia in children.

Current Investors

Sofinnova Investments, Vivo Capital, Ascendis Pharma A/S

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Healthcare Specialists, Pharmaceutical Research & Development

Website

www.visenpharma.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.